Where to buy Travatan ?
- 0.004% - travoprost ophthalmic solution;
Travatan eye drops are indicated for the reduction of elevated intraocular pressure in patients with open-angle
glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently
responsive to another intraocular pressure lowering medication.
Travatan eye drops are contraindicated in patients with hypersensitivity to travoprost, benzalkonium chloride or any other ingredients in
Travatan eye drops.
Travatan eye drops was teratogenic in rats, at an intravenous (IV) dose up to 10 mg/kg/day (250 times the MRHOD), evidenced
by an increase in the incidence of skeletal malformations as well as external and visceral malformations, such as fused sternebrae,
domed head and hydrocephaly. Travoprost was not teratogenic in rats at IV doses up to 3 mg/kg/day (75 times the MRHOD), and in
mice at subcutaneous doses up to 1.0 mg/kg/day (25 times the MRHOD).
A study in lactating rats demonstrated that radiolabeled travoprost and/or its metabolites were excreted in milk. Travatan eye drops are
not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should
be exercised when Travatan eye drops are administered to a nursing woman.
The most common ocular adverse event observed in controlled clinical studies with Travatan eye drops 0.004% was ocular
hyperemia which was reported in 35 to 50% of patients.
Approximately 3% of patients discontinued therapy due to conjunctival hyperemia.
Ocular adverse events reported at an incidence of 5 to 10% included:
- Foreign body sensation;
- Eye discomfort;
- Decreased visual acuity;
Ocular adverse events reported at an incidence of 1 to 4% included:
- Subconjunctival hemorrhage;
- Lid margin crusting;
- Iris discoloration;
- Eye disorder;
- Dry eye;
- Blurred vision;
- Abnormal vision;
Nonocular adverse events reported at a rate of 1 to 5% were:
- Urinary tract infection;
- Urinary incontinence;
- Prostate disorder;
- Gastrointestinal disorder;
- Cold syndrome;
- Chest pain;
- Back pain;
- Angina pectoris;
- Accidental injury;
Travatan eye drops recommended dosage is 1 drop in the affected eye(s) once-daily in the evening. The dosage of
Travatan eye drop should not exceed once-daily since it has been shown that more frequent administration may
decrease the intraocular pressure lowering effect.
Reduction of intraocular pressure starts approximately 2 hours after administration and the maximum effect is reached
after 12 hours.
Travatan eye drop may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than
one topical ophthalmic drug is being prescribed, the drops should be administered at least five (5) minutes apart.
Travatan eye drops 0.004% are:
- A sterile;
- Aqueous solution of travoprost (0.04 mg/mL) supplied in oval drop package system.
Travatan eye drop are supplied as a 2.5 mL solution in a 4 mL and a 5 mL solution in a 7.5 mL natural polypropylene dispenser
bottle with a natural polypropylene dropper tip and a turquoise polypropylene overcap.